Seres Therapeutics, Inc. · NASDAQ:MCRB

Seres Therapeutics — Investor Presentation (May 2023)

37 slides from Seres Therapeutics's investor presentation, May 9, 2023

  1. Slide 1: Seres Therapeutics Corporate Overview May 2023

    Seres Therapeutics Corporate Overview May 2023 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to timing of VOWST product availability; the anticipated supply and degree of market acceptance of VOWST; the potential for micro

  3. Slide 3: VOWST is the First FDA Approved Orally Administered Microbiota-Based Therapeutic

    VOWSTTM is the First FDA Approved Orally Administered Microbiota-Based Therapeutic VOWSTTM is indicated to prevent the recurrence of C. difficile infection (CDI) in individuals 18 years of age or older following antibacterial treatment for recurrent CDI (rCDI). Seres is pioneering a new modality, le

  4. Slide 4: Seres Mission: Transforming the Lives of Patients with Microbiome Therapeutics

    Seres Mission: Transforming the Lives of Patients Worldwide with Revolutionary Microbiome Therapeutics Encapsulated consortia of commensal bacteria designed to target multiple disease-relevant pathways simultaneously Bacterial Consortia Orally-formulated, using current Good Manufacturing Practices (

  5. Slide 5: Strategic Priorities

    Strategic Priorities | Expanding Microbiome Therapeutic Leadership Successfully commercialize VOWSTTM, first-in-class oral microbiome therapeutic Maximize opportunities in Infection Protection Continue research to inform further development in ulcerative colitis and immune modulation FDA approved on

  6. Slide 6: Pipeline

    Immunotherapy Collaborators INFECTION PROTECTION Preclinical Phase 1b Phase 2b FDA Approval SER-155 Bloodstream and antimicrobial-resistant bacterial infections & GvHD in allogenic hematopoietic stem cell transplant patients IMMUNE MODULATION SER-287 Ulcerative colitis4 SER-301 Ulcerative colitis4 M

  7. Slide 7: VOWST and Recurrent C. difficile Infection

    VOWSTTM and Recurrent C. difficile Infection Seres Therapeutics, Inc. © 2023

  8. Slide 8: C. difficile Infections Are an Urgent Public Health Threat

    C. difficile Infections Are an Urgent Public Health Threat High probability of recurrence >20%, usually within 1-2 weeks after completion of antibiotic therapy Symptoms include colitis and severe, watery diarrhea with up to 15 bowel movements a day Spore-forming, toxin-producing, gram-positive, anae

  9. Slide 9: VOWST ECOSPOR III Study Results

    Time point VOWST (N =90) Placebo (N =92) Relative risk (95%CI) p-value (p1/p2) n (%) of recurrences n (%) of recurrences Week 8 11 (12.4) 37 (39.8) 0.32 (0.18-0.58) <0.001 / <0.001 TRIAL DESIGN VOWST ECOSPOR III Study Results Primary endpoint: C. diff. recurrence, at up to 8 weeks VOWST (n = 90) Mul

  10. Slide 10: VOWST Phase 3 Results Published in Premier Journals

    VOWST Phase 3 Results Published in Premier Journals January 20, 2022 Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile infection in a Randomized Clinical Trial RESEARCH LETTER Survival Function for Time to Clostridioides difficile Infection

  11. Slide 11: ECOSPOR III Data: VOWST Was Well-Tolerated

    ECOSPOR III Data: VOWST Was Well-Tolerated Adverse Events (AEs) Through 8 Weeks (Safety Population)2 SER-109 (n=90) n (%) Placebo (n=92) n (%) Any adverse event 84 (93) 84 (91) Adverse event related or possibly related to SER-109 or placebo 46 (51) 48 (52) Serious adverse event3 7 (8) 15 (16) Advers

  12. Slide 12: ECOSPOR III Data: VOWST Was Well-Tolerated

    ECOSPOR III Data: VOWST Was Well-Tolerated Adverse Events (AEs) Through 8 Weeks (Safety Population)2 SER-109 (n=90) % Placebo (n=92) % Solicited* Abdominal distension 31.1 29.3 Fatigue 22.2 21.7 Constipation 14.4 10.9 Chills 11.1 7.6 Unsolicited Diarrhea 10.0 4.3 Source: VOWST Package Insert * Solic

  13. Slide 13: ECOSPOR IV Data: VOWST Was Well-Tolerated

    ECOSPOR IV Data: VOWST Was Well-Tolerated * 4 VOWST participants discontinued ECOSPOR III and enrolled in ECOSPOR IV **TEAE: treatment-emergent adverse event; SAE: serious adverse event Sims et al. JAMA Netw Open. 2023 Feb 1;6(2):e2255758.; adverse reactions from Package Insert Seres Therapeutics, I

  14. Slide 14: ECOSPOR IV Study Published in JAMA Network Open

    ECOSPOR IV Study (n=263) Published in JAMA Network Open Open label design study to assess overall safety profile through 24-week follow up: SER-109 was well-tolerated, consistent with safety profile in ECOSPOR III, and extended the safety population Recurrence-free rate: 91% similar to 88% rate obse

  15. Slide 15: New Oral Treatment Option for Adults with rCDI

    Full prescribing information available at vowst.com Highlights of Prescribing Information Indication statement VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI (rCDI) Lim

  16. Slide 16: VOWST is Highly Anticipated by Healthcare Professionals

    “ VOWST is Highly Anticipated by Healthcare Professionals Source: GI and ID survey (n=300), 2021 Dr. Carl Crawford, M.D. Assistant Professor of Clinical Medicine Division of Gastroenterology, Weill Cornell Medicine Recurrent C. difficile infection is a highly debilitating and life-threatening diseas

  17. Slide 17: HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences

    Prevention of recurrences is seen as a top treatment goal for rCDI patients Despite it being the top goal, physicians perceive standard of care as lacking efficacy at preventing recurrences As a result, preventing recurrences is also the biggest unmet need leading to heightened appetite for a produc

  18. Slide 18: Expect HCP Use of VOWST to Broaden with Product Experience

    Expect HCP Use of VOWST to Broaden with Product Experience Source: Seres market research Seres Therapeutics, Inc. © 2023 Expected initial patient types The first patient I'd give it to would be somebody who probably has it from being on prolonged antibiotics, doesn't have a lot of other comorbid ill

  19. Slide 19: Combined Field Teams to Cover Highest Potential rCDI Prescribers

    Combined Field Teams to Cover Highest Potential rCDI Prescribers Prioritize top volume and early adopting HCPs w/150 person GI sales force GI sales force covers 85% of GI practices for current inline Nestle product Average 10 years industry experience & 5 years in GI Drove ZENPEP® acceleration over

  20. Slide 20: Engaging with Key Commercial and Medicare Part D Plans

    Engaging with Key Commercial and Medicare Part D Plans to Initiate Broad Coverage * New To Market Block (NTMB) deny insurance coverage of a new therapy until it can be reviewed and covered by the health plan. Seres Therapeutics, Inc. © 2023 VOWST Launch Up to Launch + 12 months Payers utilize NTMBs*

  21. Slide 21: VOWST Delivers Compelling Value Proposition

    *Subject to specific eligibility and financial criteria Sources: 1. Rodrigues et al Infect Control Hosp Epidemiol. 2017 Feb;38(2):196-202. ; inflation adjusted from $34K in 2016 dollars to 2023 dollars 2. Optum Burden of Illness data on file VOWST Delivers Compelling Value Proposition We Are Committ

  22. Slide 22: Laying the Foundations to Ultimately Transform Standard of Care

    Laying the Foundations to Ultimately Transform Standard of Care and Achieve Potential Initial Focus Expanded Focus Increase HCP awareness and trial of an entirely new modality Provide positive experience Enhance hospital outflow Engage payers to build coverage Drive repeat use among higher-volume HC

  23. Slide 23: Co-commercializing VOWST in the United States with 50/50 Profit Sharing

    Co-commercializing VOWST in the United States with 50/50 profit sharing per July 2021 agreement, extending our global strategic collaboration Seres Therapeutics, Inc. © 2023

  24. Slide 24: Seres and Nestlé Health Science Resources and Complementary Capabilities

    Seres and Nestlé Health Science Have Full Suite of Resources and Complementary Capabilities to Support VOWSTTM Launch Market Access and Reimbursement Specialty Product Distribution Patient Support Services Medical Affairs Data and Insights Commercial Infrastructure Key Customer Relationships Seres T

  25. Slide 25: Well Positioned to Supply Commercial Demand at Launch and Beyond

    Well Positioned to Supply Commercial Demand at Launch and Beyond VOWSTTM commercial supply Note: Seres and Bacthera collaboration press release issued Nov. 10, 2021 + 10+ years of Seres technology & facility investment for anaerobic bacterial therapeutics Joint venture between Chr. Hansen and Lonza

  26. Slide 26: SER-155 and Infection Protection Franchise

    SER-155 and Infection Protection Franchise Seres Therapeutics, Inc. © 2023

  27. Slide 27: Antimicrobial Resistant Infections - Urgent Public Health Threat

    Antimicrobial Resistant Infections - Urgent Public Health Threat Limited innovation despite substantial and growing impact Declared “one of the world’s most urgent threats” $20 billion excess direct healthcare costs 35,000 deaths per year in US Major burden to society Many high-risk patient populati

  28. Slide 28: SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance

    SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD in Allogeneic HSCT Enrollment ongoing in SER-155 Phase 1b Cohort 2 a randomized, double-blind, placebo-controlled study Expect to release topline results in mid-2024 SER-155 is an oral, cultivated consortium,

  29. Slide 29: SER-155 Designed to Modulate Targets Following Allogeneic HSCT

    SER-155 Designed to Modulate Targets that Address Leading Causes of Mortality Following Allogeneic HSCT (allo-HSCT) Consortium of unique, human commensal bacterial strains Cultivated and encapsulated for oral delivery Strain selection based on broad pre-clinical screening for defined functions and i

  30. Slide 30: ESKAPE Pathogen Domination Was Rare and Transient in Cohort 1

    ESKAPE pathogen domination* in SER-155 administered subjects observed at rates substantially lower than reference cohort ESKAPE Pathogen Domination was Rare and Transient in Cohort 1 SER-155 Cohort 1 From HSCT Day 0-30, 11% of patients (1 subject, Fig.1 blue line) From HSCT day 0-100, 22% of patient

  31. Slide 31: SER-155 Was Generally Well-Tolerated in Cohort 1

    SER-155 Was Generally Well-Tolerated in Cohort 1 (Day 100 Data) TEAE: treatment-emergent adverse event; SAE: serious adverse event; AESI: adverse event of special interest; SUSAR: suspected unexpected serious adverse reaction TEAEs observed as expected in this patient population All subjects experie

  32. Slide 32: SER-155 Could Become Core Part of Allogeneic HSCT Treatment Regimen

    SER-155 Could Become Core Part of Allogeneic HSCT Treatment Regimen Unique potential clinical and economic value for allogeneic HSCT patients Double benefit of reducing infections and GvHD, 2 of 3 leading causes of mortality at 1 year Avoids costs of post-transplant complications: $181K average addi

  33. Slide 33: Seres' Path Forward

    Seres’ Path Forward Seres Therapeutics, Inc. © 2023

  34. Slide 34: Maximizing the Opportunity in Infection Protection

    VOWST rCDI SER-155 BSI & GvHD in allogeneic HSCT recipients Broad preclinical portfolio Driving to an additional clinical development program in 2023 Potentially 2+ additional programs within 3 years SER-155: Therapeutic adjacency to SER-109 Phase 1b study ongoing in cohort 2 Additional Opportunitie

  35. Slide 35: Well Positioned to Bring VOWST to Patients and Advance Our Pipeline

    Seres is Well Positioned to Bring VOWST to Patients and Advance Our Pipeline $125 million milestone due to Seres with approval Secured up to $250 million debt facility; $110 million funded at closing Replaces existing debt facility * Net of payout to retire existing debt and fees 3/31/2023 cash bala

  36. Slide 36: Well Positioned to Extend Microbiome Therapeutic Leadership in 2023

    SER-155 Phase 1b in Cohort 2 with successful engraftment and reduced pathogen domination in Cohort 1 Ongoing preclinical programs with potential to address large immunocompromised patient populations Well Positioned to Extend Microbiome Therapeutic Leadership in 2023 Opportunities in Infection Prote

  37. Slide 37: Continued Microbiome Therapeutic Leadership and Value Creation

    Continued Microbiome Therapeutic Leadership, Anticipated Compelling Growth and Value Creation Advancing opportunities in Infection Protection and other therapeutic areas VOWSTTM approved; commercialization underway in rCDI VOWSTTM transforming standard of care for a broad population of rCDI patients

Seres Therapeutics — Investor Presentation (May 2023) on 6ix